Efficacy and Safety of Hydromorphone-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia
Status:
Recruiting
Trial end date:
2023-10-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effects of three different doses of hydromorphone
combined with ropivacaine and sufentanil combined with ropivacaine in epidural labor
analgesia through prospective clinical trials, so as to explore whether hydromorphone
combined with ropivacaine has advantages in epidural labor analgesia, and find out the
optimal dose of hydromorphone.
Participants will be randomly allocated to four groups : Group 1, Group 2, Group 3 and Group
4. For those in Group 1 : they will be administered with 15 ug/ml hydromorphone and 0.08%
ropivacaine for epidural labor analgesia, For those in Group 2 : they will be administered
with17.5 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in
Group 3 : they will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine for
epidural labor analgesia, For those in Group 4 : they will be administered with 0.4 ug/ml
sufentanil and 0.08% ropivacaine for epidural labor analgesia.
The goal of this clinical trial is to provide a new treatment option for pregnant women in
epidural labor analgesia, and to provide a basis for hydromorphone combined with ropivacaine
in epidural labor analgesia.
Phase:
Phase 2
Details
Lead Sponsor:
Maternal and Child Health Hospital of Hubei Province